Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 6/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29217890 | 0.81 | KIF11 (0.42) | WDR5HSD11B1CCR2 | |
| SCHEMBL16019376 | 0.81 | SMN1; SMN2 (0.37) | WDR5CCR2PTGDR2TSHRGLA | |
| SCHEMBL23291772 | 0.81 | PTGDR2 (0.38) | WDR5PTGDR2TSHRALDH1A1 | |
| SCHEMBL29295504 | 0.80 | SMN1; SMN2 (0.39) | WDR5GLASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12179229 | 0.79 | ALDH1A1 (0.38) | HSD11B1TSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL23291833 | 0.77 | WDR5 (0.35) | WDR5CCR2TSHRGLASMN1; SMN2 | |
| SCHEMBL7847441 | 0.76 | PTGDR2 (0.40) | HSD11B1PTGDR2ALDH1A1 | |
| SCHEMBL3112984 | 0.76 | CCR2 (0.44) | WDR5CCR2TSHRGLASMN1; SMN2 | |
| SCHEMBL10960303 | 0.75 | WDR5 (0.56) | WDR5 | |
| SCHEMBL4472584 | 0.74 | RAB9A (0.38) | HSD11B1PTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020148325-A1 | NEUTRAL LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-07-23 | — | — | WO | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| CN-101248049-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1910308-A1 | IMIDAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002563-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002563-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | WDR5 4341/4885HSD11B1 105/4885CCR2 365/4885 |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | WDR5 4546/4885HSD11B1 161/4885CCR2 292/4885 |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | WDR5 3248/4885HSD11B1 934/4885CCR2 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.